A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Public ClinicalTrials.gov record NCT02781727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD)
Study identification
- NCT ID
- NCT02781727
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Enrollment
- 162 participants
Conditions and interventions
Conditions
Interventions
- Once weekly subcutaneous injection of TransCon hGH Drug
- Once daily subcutaneous injection of Genotropin Drug
Drug
Eligibility (public fields only)
- Age range
- 3 Years to 12 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2016
- Primary completion
- Jan 16, 2019
- Completion
- Jan 16, 2019
- Last update posted
- Jul 6, 2026
2016 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ascendis Pharma Investigational Site | Birmingham | Alabama | 35233 | — |
| Ascendis Pharma Investigational Site | Little Rock | Arkansas | 72202 | — |
| Ascendis Pharma Investigational Site | Los Angeles | California | 90048 | — |
| Ascendis Pharma Investigational Site | Orange | California | 92868 | — |
| Ascendis Pharma Investigational Site | Centennial | Colorado | 80112 | — |
| Ascendis Pharma Investigational Site | Jacksonville | Florida | 32207 | — |
| Ascendis Pharma Investigational Site | Orlando | Florida | 32806 | — |
| Ascendis Pharma Investigational Site | Saint Paul | Minnesota | 55102 | — |
| Ascendis Pharma Investigational Site | Jackson | Mississippi | 39216 | — |
| Ascendis Pharma Investigational Site | Lebanon | New Hampshire | 03756 | — |
| Ascendis Pharma Investigational Site | Mineola | New York | 11501 | — |
| Ascendis Pharma Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Ascendis Pharma Investigational Site | Portland | Oregon | 97239 | — |
| Ascendis Pharma Investigational Site | Dallas | Texas | 75235 | — |
| Ascendis Pharma Investigational Site | Fort Worth | Texas | 76104 | — |
| Ascendis Pharma Investigational Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02781727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 6, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02781727 live on ClinicalTrials.gov.